Avid Bioservices has signed a manufacturing supply and technology transfer agreement with Arius Research. The agreement covers Arius’ lead cancer stem cell antibody, which targets a novel epitope of CD44 found in breast, colon and prostate cancers. Avid will begin manufacturing drug supply under cGMP  for human trials that Arius plans to initiate in 2008. “This new agreement reflects our extensive experience and broad capabilities in manufacturing monoclonal antibodies, as well as...